0 273

Cited 0 times in

Cited 77 times in

A systematic review and meta-analysis of long-term sequelae of COVID-19 2-year after SARS-CoV-2 infection: A call to action for neurological, physical, and psychological sciences

DC Field Value Language
dc.contributor.authorRahmati, Masoud-
dc.contributor.authorUdeh, Raphael-
dc.contributor.authorYon, Dong Keon-
dc.contributor.authorLee, Seung Won-
dc.contributor.authorDolja-Gore, Xenia-
dc.contributor.authorMcEVoy, Mark-
dc.contributor.authorKenna, Tony-
dc.contributor.authorJacob, Louis-
dc.contributor.authorSanchez, Guillermo F. Lopez F.-
dc.contributor.authorKoyanagi, Ai-
dc.contributor.authorShin, Jae Il-
dc.contributor.authorSmith, Lee-
dc.date.accessioned2024-01-03T01:10:00Z-
dc.date.available2024-01-03T01:10:00Z-
dc.date.created2024-01-16-
dc.date.issued2023-06-
dc.identifier.issn0146-6615-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/197474-
dc.description.abstractLong-term sequelae conditions of COVID-19 at least 2-year following SARS-CoV-2 infection are unclear and little is known about their prevalence, longitudinal trajectory, and potential risk factors. Therefore, we conducted a comprehensive meta-analysis of survivors' health-related consequences and sequelae at 2-year following SARS-CoV-2 infection. PubMed/MEDLINE, CENTRAL, and EMBASE were systematically searched up to February 10, 2023. A systematic review and meta-analysis were performed to calculate the pooled effect size, expressed as event rate (ER) with corresponding 95% confidence interval (CI) of each outcome. Twelve studies involving 1 289 044 participants from 11 countries were included. A total of 41.7% of COVID-19 survivors experienced at least one unresolved symptom and 14.1% were unable to return to work at 2-year after SARS-CoV-2 infection. The most frequent symptoms and investigated findings at 2-year after SARS-CoV-2 infection were fatigue (27.4%; 95% CI 17%-40.9%), sleep difficulties (25.1%; 95% CI 22.4%-27.9%), impaired diffusion capacity for carbon monoxide (24.6%; 95% CI 10.8%-46.9%), hair loss (10.2%; 95% CI 7.3%-14.2%), and dyspnea (10.1%; 95% CI 4.3%-21.9%). Individuals with severe infection suffered more from anxiety (OR = 1.69, 95% CI 1.17-2.44) and had more impairments in forced vital capacity (OR = 9.70, 95% CI 1.94-48.41), total lung capacity (OR = 3.51, 95% CI 1.77-6.99), and residual volume (OR = 3.35, 95% CI 1.85-6.07) after recovery. Existing evidence suggest that participants with a higher risk of long-term sequelae were older, mostly female, had pre-existing medical comorbidities, with more severe status, underwent corticosteroid therapy, and higher inflammation at acute infection. Our findings suggest that 2-year after recovery from SARS-CoV-2 infection, 41.7% of survivors still suffer from either neurological, physical, and psychological sequela. These findings indicate that there is an urgent need to preclude persistent or emerging long-term sequelae and provide intervention strategies to reduce the risk of long COVID.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherWiley-Liss-
dc.relation.isPartOfJOURNAL OF MEDICAL VIROLOGY-
dc.relation.isPartOfJOURNAL OF MEDICAL VIROLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleA systematic review and meta-analysis of long-term sequelae of COVID-19 2-year after SARS-CoV-2 infection: A call to action for neurological, physical, and psychological sciences-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pediatrics (소아과학교실)-
dc.contributor.googleauthorRahmati, Masoud-
dc.contributor.googleauthorUdeh, Raphael-
dc.contributor.googleauthorYon, Dong Keon-
dc.contributor.googleauthorLee, Seung Won-
dc.contributor.googleauthorDolja-Gore, Xenia-
dc.contributor.googleauthorMcEVoy, Mark-
dc.contributor.googleauthorKenna, Tony-
dc.contributor.googleauthorJacob, Louis-
dc.contributor.googleauthorSanchez, Guillermo F. Lopez F.-
dc.contributor.googleauthorKoyanagi, Ai-
dc.contributor.googleauthorShin, Jae Il-
dc.contributor.googleauthorSmith, Lee-
dc.identifier.doi10.1002/jmv.28852-
dc.relation.journalcodeJ01587-
dc.identifier.eissn1096-9071-
dc.identifier.pmid37288652-
dc.subject.keywordCOVID-19-
dc.subject.keywordlong COVID-
dc.subject.keywordmeta-analysis-
dc.subject.keywordprevalence-
dc.subject.keywordSARS-CoV-2-
dc.contributor.alternativeNameShin, Jae Il-
dc.contributor.affiliatedAuthorShin, Jae Il-
dc.identifier.scopusid2-s2.0-85161181261-
dc.identifier.wosid001022881500001-
dc.citation.volume95-
dc.citation.number6-
dc.identifier.bibliographicCitationJOURNAL OF MEDICAL VIROLOGY, Vol.95(6), 2023-06-
dc.identifier.rimsid81513-
dc.type.rimsART-
dc.description.journalClass1-
dc.description.journalClass1-
dc.subject.keywordAuthorCOVID-19-
dc.subject.keywordAuthorlong COVID-
dc.subject.keywordAuthormeta-analysis-
dc.subject.keywordAuthorprevalence-
dc.subject.keywordAuthorSARS-CoV-2-
dc.subject.keywordPlusONE-YEAR OUTCOMES-
dc.subject.keywordPlusFOLLOW-UP-
dc.subject.keywordPlusSURVIVORS-
dc.subject.keywordPlusQUALITY-
dc.subject.keywordPlusIMPACT-
dc.subject.keywordPlusCHINA-
dc.type.docTypeArticle-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalWebOfScienceCategoryVirology-
dc.relation.journalResearchAreaVirology-
dc.identifier.articlenoe28852-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.